HWAM
RAPT

Hennion & Walsh Asset Management’s RAPT Therapeutics RAPT Stock Holding History

Hennion & Walsh Asset Management’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-4,780
Closed -$46.7K – 945
2025
Q1 		$46.7K Sell
4,780
-1,102
-19% -$10.8K ﹤0.01% 864
2024
Q4 		$74.3K Sell
5,882
-109
-2% -$1.38K ﹤0.01% 846
2024
Q3 		$96.3K Sell
5,991
-75
-1% -$1.52K ﹤0.01% 860
2024
Q2 		$148K Buy
6,066
+478
+9% +$22.1K 0.01% 824
2024
Q1 		$401K Buy
5,588
+136
+2% +$18.9K 0.02% 621
2023
Q4 		$1.08M Buy
5,452
+381
+8% +$47.2K 0.06% 386
2023
Q3 		$674K Buy
5,071
+2,395
+89% +$391K 0.04% 447
2023
Q2 		$400K Buy
+2,676
New +$417K 0.02% 577

Other funds holding RAPT

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Hennion & Walsh Asset Management's RAPT Position: Q2 2025 in Review

Hennion & Walsh Asset Management sold out of RAPT Therapeutics (RAPT) in Q2 2025, closing a stake of 4,780 shares — an estimated $46.7K sold.

Hennion & Walsh Asset Management first reported a position in RAPT in Q2 2023 and held it in 8 quarters. The position peaked at $1.08M in Q4 2023. 50 funds tracked by Wall St. Rank hold RAPT as of Q2 2025.

  • Hennion & Walsh Asset Management reported no remaining RAPT Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Hennion & Walsh Asset Management sold 4,780 RAPT Therapeutics shares in Q2 2025, an estimated $46.7K.
  • Hennion & Walsh Asset Management first reported a position in RAPT Therapeutics in Q2 2023 and held it in 8 quarters.
  • Hennion & Walsh Asset Management's RAPT Therapeutics position peaked at $1.08M in Q4 2023.
  • 50 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q2 2025.

Based on Hennion & Walsh Asset Management's 13F filing for Q2 2025, filed 7 Aug 2025.